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Basic principles of boron neutron capture 
therapy (BNCT)
BNCT is a technique for the treatment of solid tumors. 
BNCT is considered a binary technique because it involves 
two components that exert little or no action individually 
but induce a significant effect when they combine. BNCT 
is based on the combination of neutron irradiation and the 
administration of 10B compounds that are incorporated 
selectively by tumor tissue via different mechanisms, 
depending on the boron carrier. The capture reaction 
between a thermal neutron and a boron-10 nucleus gives 
rise to the formation of a 7Li nucleus and an alpha particle. 
These densely ionizing particles have high linear energy 
transfer (LET), high relative biological efficacy (RBE) and 
travel only a short distance in tissue (5–9 micrometers). The 
fact that high LET particles have a short range in tissue 
makes the microdistribution of boron relative to a sensitive 
target of great relevance to therapeutic efficacy. Damage is 
largely circumscribed to tumor tissue where 10B atoms are 
preferentially localized (1,2). Thus, BNCT targets tumor 
tissue selectively, sparing healthy tissue. In the case of 
standard radiotherapy, selective tumor targeting is based on 
identification of the tumor volume and delimitation of its 
boundaries. However, in the case of BNCT, selective tumor 
targeting is biological/biochemical, relying on preferential 
incorporation of boron to tumor. In this way, BNCT would 
be adequate to treat infiltrating cells or micrometastases 
that cannot be identified by imaging techniques (3). 
BNCT involves a mixed irradiation field composed of 
the boron dose component that affects tumor selectively 
and a background dose that affects tumor and healthy tissue 
alike. The background dose includes the low-LET gamma 
rays that contaminate the neutron beam and those resulting 
from the capture of a thermal neutron by a hydrogen 
atom, high LET protons resulting from the scattering of 
fast neutrons and high-LET protons that originate in the 
capture of a thermal neutron by a nitrogen atom. The 
design of BNCT protocols strives to maximize the ratio 
between the tumor selective boron component of the dose 
and the non-selective background dose (1). 
BNCT clinical trials
BNCT clinical trials for the treatment of glioblastoma 
multiforme, melanoma, recurrent head and neck tumors, 
and liver metastases performed in the United States, Japan, 
Europe, Argentina and Taiwan have been performed 
employing mostly nuclear reactors (4-7). Recent clinical 
BNCT trials in Japan have explored the potential 
therapeutic advantage of BNCT to treat other tumors and 
localizations such as recurrent hepatic and gastrointestinal 
cancer, lung cancer and extra-mammary Paget’s disease 
(8-10). Overall clinical results to date show a therapeutic 
advantage for BNCT associated to an improvement in 
quality of life and prolonged survival (11). Nevertheless, 
optimization of BNCT is clearly necessary to improve 
therapeutic efficacy and reduce associated toxic side-effects. 
The use of hospital-based accelerators as the neutron source 
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rather than nuclear reactors will promote new clinical trials 
for existing and new treatment targets. 
Translational radiobiological BNCT studies for 
head and neck cancer
Translational radiobiological studies in appropriate in vivo 
experimental models are essential to the advancement of 
BNCT for different pathologies. Our first BNCT studies 
were devoted to explore what was then a new application 
of BNCT, i.e., the treatment of head and neck cancer. We 
provided evidence of the success of BNCT employing the 
boron compound boronophenylalanine (BPA) as the boron 
carrier to treat head and neck cancer in an oral cancer 
model in the hamster cheek pouch (91% tumor response 
[partial remission + complete remission] prescribing 5 Gy 
absorbed dose to tumor). Mucositis in the radiosensitive 
precancerous tissue surrounding tumors (precancerous 
tissue mimics field-cancerized tissue in human oral cancer) 
was reversible but limited the dose that could be applied 
to tumor. The dose of 5 Gy prescribed to tumor was 
based on pilot studies to establish the maximum dose that 
could be administered to tumor without exceeding the 
radiotolerance of precancerous tissue, the dose-limiting 
tissue. In later studies we prescribed dose to precancerous 
tissue, considered as the “organ at risk” within the 
treatment volume. This study suggested, for the first time, 
that BNCT could induce a robust tumor response in head 
and neck cancer with acceptable toxicity in dose-limiting 
precancerous tissue (12,13). These translational studies 
contributed to the first clinical BNCT trial for head and 
neck cancer (14). 
Seeking to improve BNCT therapeutic efficacy, 
we envisioned the potential value of combining the 
boron agents BPA and decahydrodecaborate (GB-10). 
Homogeneous tumor boron targeting is essential to the 
success of BNCT because those cells that are loaded with 
insufficient 10B atoms (<109 10B atoms) will fail to respond to 
BNCT and cause the failure of treatment. A combination 
of boron carriers that are incorporated to cells by different 
mechanisms will favor tumor boron targeting homogeneity 
and concomitant improved therapeutic efficacy of BNCT 
(15,16). Merely as a control group, we explored the boron 
biodistribution of GB-10 in the oral cancer model in the 
hamster cheek pouch. GB-10 is a largely diffusive agent 
that was proposed as a boron carrier for the treatment 
of brain tumors with BNCT because it does not traverse 
the intact blood brain barrier (BBB) but can enter tumors 
surrounded by a disrupted BBB. We thus did not expect 
GB-10 to target tumor preferentially in the case of tumors 
outside brain and assumed that it would not serve as a 
boron carrier used alone for oral cancer. In effect, our 
boron biodistribution studies showed that GB-10 did 
not target hamster Squamous Cell Carcinomas (SCC) 
selectively (17). However, counter-intuitively, we showed 
that even when GB-10 is not incorporated selectively by 
tumor, when used as a boron carrier for BNCT in our oral 
cancer model, it leads to selective tumor damage with no 
concomitant precancerous and normal tissue toxicity. GB-
10-BNCT induced a 70% tumor response at approximately 
8 Gy absorbed dose to tumor, associated to only mild and 
reversible mucositis in dose-limiting precancerous tissue. 
The fact that GB-10-BNCT induced milder toxicity than 
BPA-BNCT in dose-limiting precancerous tissue allowed 
us to escalate tumor dose. This new paradigm in BNCT 
would be based on a selective effect of GB-10-BNCT on 
the more radiosensitive aberrant tumor vasculature while 
precancerous and normal tissues that do not have aberrant 
vasculature are preserved (18). If we had relied only on 
biodistribution studies (17), we would have discarded GB-
10 as a boron compound administered alone for BNCT 
of tumors of the head and neck due to its lack of tumor 
selectivity. However, actual in vivo BNCT studies showed 
that a selective lethal effect on tumor can occur as a result 
of a selective effect of GB-10-BNCT on aberrant blood 
vessels in tumor instead of the selective incorporation of the 
boron agent by tumor tissue. In addition, the other side of 
the coin of a lack of selective tumor vs blood, precancerous 
and normal tissue uptake of GB-10, is homogeneous boron 
targeting within the tumor, a “plus” for therapeutic success. 
Conversely, BPA is taken up selectively by tumor by active 
transport using the amino acid LAT1 transport system that 
is overexpressed in metabolically active cells. The down-
side of BPA’s selective tumor uptake is that, because it is 
associated to enhanced metabolic activity, boron targeting 
within the tumor is heterogeneous, admittedly a “minus” 
for therapeutic success (16,18). 
The assessment of BNCT mediated by BPA + GB-10 
administered together did in effect enhance therapeutic 
effect, conceivably by bringing together in a single 
treatment the selective effect of GB-10-BNCT on aberrant 
blood vessels and the “cell by cell” therapeutic effect 
of BPA-BNCT and, additionally, by improving tumor 
boron targeting homogeneity. Also, an enhanced tumor 
response rate (93% at approximately 8 Gy absorbed dose to 
tumor), was associated to milder mucositis in precancerous 
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tissue than in the case of BNCT mediated by BPA (18). 
Mucositis is a particular concern associated to BNCT 
mediated by BPA. This is not a surprising finding because 
mucositis originates in damage to the basal layer (19), 
exactly the site where BPA would accumulate (13). The 
largely diffusive boron compound GB-10 does not 
target the basal layer preferentially and GB-10-BNCT 
(delivered at therapeutically useful doses), induces only 
mild, reversible, mucositis in precancerous tissue. Boron 
targeting homogeneity in tumor, achieved by administering 
combinations of boron compounds, or a largely diffusive 
boron compound such as GB-10, also improved the 
complete remission rate induced by BNCT in the larger 
tumors, the most difficult tumors to treat (18). 
Because optimizing tumor boron targeting is the best way 
to maximize the therapeutic efficacy of BNCT, widespread 
international efforts are focused on the development of the 
“ideal” boron compound for BNCT, i.e., it will be non-
toxic at therapeutic dose levels, it will be tumor selective, 
it will enter all tumor cells and will be an efficient carrier 
of 10B to tumor, placing 10B in the vicinity of radiosensitive 
intracellular targets. BNCT literature typically stresses 
the importance of a high (≥3/1) tumor/normal tissue and 
tumor/blood boron concentration ratio. While selective 
tumor uptake is an asset to BNCT therapeutic advantage, 
it is only part of the story. For example, adhering to this 
concept would have led us to rule out the use of GB-10 
as a boron compound to be used in BNCT of head and 
neck cancer (20,21). Absolute boron concentration in 
tumor is of paramount importance to response. If boron 
content falls below approximately 109 atoms 10B/cell, the 
10B(n,α)7Li capture reactions will be insufficient to yield a 
lethal effect. Also, high absolute tumor boron concentration 
will allow for shorter irradiation times to reach the same 
absorbed dose in tumor. Shortening irradiation time will 
lead to a reduction in the background dose that affects 
normal tissue, regardless of its low boron concentration, 
and a concomitant increase in the proportion of the boron 
component of the dose that is tumor selective. Finally, 
because α and lithium particles travel short distances 
(approximately the diameter of a cell), the microlocalization 
of boron relative to radiosensitive subcellular targets will 
condition the outcome of BNCT (2). The “ideal” boron 
compound has yet to be developed—definitely no easy task. 
Furthermore, its extrapolation to a clinical scenario would 
be extremely costly and time-consuming. In the US for 
example, only 5 of the 10,000 general medicinal compounds 
that are developed enter clinical trials. Finally, only one 
of these is typically approved for treatment by FDA. The 
process “from bench to bedside” takes typically 10 years and 
costs over 1,000 million US dollars (22). 
Although several of our translational studies have been 
devoted to the assessment of novel boron compounds (e.g., 
23,24), our efforts have been largely focused on developing 
strategies to improve boron uptake and distribution 
employing compounds already approved for their use in 
humans such as BPA, GB-10, sodium borocaptate (BSH) 
and boric acid (BA). This approach can be used to shorten 
the distance between translational research and clinical 
evaluation. In addition, the findings can be then applied to a 
more ideal boron compound in the future (20). 
Our strategy of “thinking out of the box” that led us 
to show, for the first time, the therapeutic efficacy of 
BNCT for head and neck cancer and the selective effect 
of BNCT mediated by GB-10, a boron compound that 
is not incorporated to tumor tissue selectively, prompted 
us to search for ways to improve the incorporation and 
distribution of boron in tissue employing the boron 
compounds that are approved for their use in humans, 
knowing they are not ideal. 
We developed Sequential-BNCT, a novel strategy 
based on the sequential application of BPA-BNCT and 
GB-10-BNCT with an interval of 24–48 hours between 
applications (25). This treatment modality is based on 
radiobiological findings of our group and others. The first 
application would reduce interstitial fluid pressure and give 
rise to void space as a result of cell death. These effects 
would favor intratumoral delivery of GB-10 in the second 
application, improving tumor boron targeting homogeneity. 
This strategy also profits from the benefits of combining 
boron compounds. The brief interval between applications 
would avoid tumor re-population but would favor targeting 
of tumor cell populations that failed to respond to the first 
application. Sequential BNCT enhanced tumor response 
(partial remission + complete remission) vs a dose-matched 
single application of BNCT mediated by (GB-10+BPA) 
from 75% to >90%, with an improvement in complete 
remission from 50% to 70%. This potentiation of the 
therapeutic effect of BNCT employing Sequential-BNCT 
did not exacerbate mucositis in precancerous tissue, the 
toxic effect that limits the dose that can be applied to tumor. 
Pursuing strategies to improve tumor boron targeting, 
we identified the need to fix the defective vascular system in 
tumors. The abnormal, faulty structure of aberrant tumor 
blood vessels leads to deficient distribution of blood-borne 
therapeutic agents. We performed transient normalization 
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of defective tumor blood vessels in the oral cancer model 
in the hamster cheek pouch. We employed thalidomide 
(also approved for use in the humans) as an anti-angiogenic 
drug, striving to improve boron distribution in the tumor. 
We administered BPA in the normalization window. Our 
working hypothesis was that boron concentration in tumor 
would rise as a result of blood vessel normalization before 
the administration of BPA. Surprisingly, ICP-MS gross 
boron concentration measurements did not show the 
expected increase in tumor boron concentration. Perplexed, 
we turned to boron microdistribution studies and actual 
radiobiological BNCT experiments searching for an 
answer. Pre-treatment to achieve transient normalization 
of tumor blood vessels before administering BPA enhanced 
tumor response from 67% to 84%, with an increase in 
complete tumor response from 43% to 56%. Our boron 
biodistribution studies showed that this effect could not be 
ascribed to an increase in gross boron content. However, 
neutron autoradiography studies revealed that a normalized 
vascular system improved boron targeting homogeneity 
in tumors (26). This would be the mechanism behind 
enhanced tumor response. Rather than increase total boron 
uptake, normalization would lead to improved distribution 
of boron to a larger proportion of tumor cells. 
We then went on to combine normalization of aberrant 
tumor blood vessels and Sequential-BNCT in the hamster 
oral cancer model. This combined treatment strategy 
yielded a remarkable tumor response (100% tumor response 
and 87% complete tumor remission). Neither associated 
toxicity in normal tissue nor severe mucositis in dose-
limiting precancerous tissue were observed (27). 
Further seeking to favor boron delivery and distribution 
in tumor, employing boron compounds approved for 
their use in humans, we examined the potential capacity 
of electroporation (EP) to optimize the uptake and 
microdistribution of GB-10 in the model of oral cancer in 
hamster. EP involves the localized application of pulsed 
fields and was approved by the European Community 
to improve the delivery of chemotherapeutic drugs in 
cutaneous and subcutaneous tumors. EP was performed 
individually in each pouch tumor 10 minutes after 
administering GB-10 and irradiation was performed 2 hours 
and 50 minutes after EP, matching neutron fluence with the 
GB-10-BNCT protocol that did not include EP. BNCT 
mediated by GB-10 prescribing 4 Gy absorbed dose to 
tumor induced 48% tumor response (complete remission + 
partial remission) with only mild mucositis in precancerous 
tissue. EP induced a significant rise in tumor response from 
48% to 92%, with a remarkable improvement in complete 
remission in small tumors (<10 mm3) from 7% to 65%. 
The enhancement in therapeutic efficacy induced by EP 
correlated with the finding of a significant increase in gross 
boron concentration in tumor and variations in the relative 
microdistribution of GB-10 in parenchyma and stroma. 
The fact that gross boron content and microdistribution 
did not show EP-induced variations in precancerous tissue 
would explain why an improved tumor response would not 
bear a cost in terms of toxicity in precancerous tissue (28). 
Another issue that requires attention is the feasibility of 
re-treatment in the case of insufficient tumor control, local 
recurrence and second primary tumors that develop from 
field cancerized tissue. In principle, if the first treatment was 
applied prescribing the maximum dose tolerated by the “organ 
at risk” (or the tissue that limits the dose that can be applied 
to tumor), re-treatment would not be possible. However, 
we showed in the oral cancer model in hamster, that a 
double application of BNCT (that involves re-treatment at 
full dose) mediated by BPA, BPA + GB-10 or MAC-TAC 
boronated liposomes with an interval of 4–6 weeks between 
applications was therapeutically effective and did not exceed 
radiotolerance of the dose-limiting precancerous tissue 
(23,24,29). This would be possible due to the dose gradient 
that can be achieved with BNCT for tumor vs. normal 
tissue.
Novel applications of BNCT: translational 
research
We went on to show the therapeutic efficacy of BNCT 
mediated by BPA and BPA+GB-10 in models of liver 
metastases (30) and lung metastases of colon carcinoma in 
BDIX rats (31), providing evidence that the findings for 
head and neck cancer also held true for other pathologies 
and localizations. 
Changing gears, we showed the efficacy of boron 
neutron capture synovectomy (BNCS) mediated by the 
intra-articular administration of GB-10 or BPA to treat 
Rheumatoid Arthritis employing an antigen induced 
arthritis (AIA) model in New Zealand rabbits. While 
biodistribution studies showed that synovium boron 
targeting selectivity vs dose-limiting healthy cartilage was 
only marginal, follow-up after BNCS showed that the 
clinical symptoms, MRI and histological features of AIA 
had reverted 2 months after treatment. A selective effect 
of BNCS on pathological synovium vs articular cartilage 
was observed despite a failure of GB-10 and BPA to target 
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synovium selectively. This phenomenon could be attributed 
to the fact that articular cartilage is relatively radioresistant 
(32,33). 
Having demonstrated the direct effect of BNCT 
on tumor in different in vivo animal models employing 
different treatment strategies, we showed, for the first 
time, the abscopal effect of BNCT in an ectopic model of 
colon carcinoma in BDIX rats (34). The abscopal effect is 
described as the inhibitory action of standard radiotherapy 
on tumor growth in an area that was not irradiated and 
would be mediated by radiation-induced immune responses. 
Our studies provided, for the first time, proof of principle 
of the abscopal effect of BNCT. 
Clinical-veterinary BNCT studies
Our long and fruitful, albeit sometimes zigzagging, road of 
translational in vivo BNCT studies led us to our ongoing 
clinical-veterinary BNCT studies at the RA-6 Nuclear 
Reactor in terminal cats and dogs with head and neck cancer 
with no other therapeutic alternative. Our data to date in 6 
cats (35,36) and 5 dogs (ongoing studies) reveal that BPA-
BNCT can improve the clinical condition of the veterinary 
patients, prolong survival with good quality of life and 
partially control tumors with only slight-moderate and 
reversible associated toxicity. Also, in a clinical-veterinary 
scenario, we were able to show the safety and therapeutic 
effect of full dose re-treatment with BNCT in a case of 
tumor recurrence. 
Conclusions
Our translational research has been devoted to optimize 
BNCT for different pathologies. In an attempt to pave 
the road to clinical evaluation, we have largely used 
novel approaches that combine boron compounds and 
techniques approved for their use in humans, i.e., (I) the 
combination of boron compounds with different properties 
and uptake mechanisms (GB-10 + BPA) to improve boron 
targeting homogeneity in tumor; (II) the use of GB-10, 
a boron carrier that is not tumor selective, that achieves 
homogeneous tumor boron targeting and a selective 
effect on tumor associated with only mild mucositis in 
precancerous tissue; (III) Sequential BNCT, a strategy based 
on the sequential application of BPA-BNCT and GB-10-
BNCT with an interval of 24-48 hs between applications; 
(IV) transient normalization of aberrant tumor blood vessels 
prior to the administration of BPA to fix the flawed delivery 
system and improve boron microdistribution in tumor; (V) 
combination of aberrant blood vessel normalization and 
Sequential BNCT; and (VI) EP to optimize the uptake and 
microdistribution of boron in tumor. 
Translational BNCT studies in in vivo animal models are 
essential to design novel, safe and effective clinical BNCT 
protocols for existing or new targets for BNCT. Team-work 
is equally essential to the advancement of BNCT. 
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